世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
静脈内治療と静脈アクセス市場：タイプ別（埋め込み型ポート、静脈内カテーテル、皮下注射針、輸液ポンプ、その他）、医療用途別（体積拡張、投薬管理、血液ベース製品、栄養・緩衝液）、エンドユーザー別（病院、外来手術センター、診療所）。世界の機会分析および産業予測、2020-2030年Intravenous (IV) Therapy and Vein Access Market By Type (Implantable Ports, Intravenous Catheters, Hypodermic Needles, Infusion Pumps, Other), By Medical Application (Volume Expander, Medication Administration, Blood Based Products, Nutrition And Buffer Solution), By End User (Hospitals, Ambulatory Surgical Center, Clinics): Global Opportunity Analysis and Industry Forecast, 2020-2030 世界の静脈内（IV）療法と静脈アクセス市場は、2020年に228億893万ドルとなり、2021年から2030年までのCAGRは5.2%を記録し、2030年には375億3,718万ドルに達すると予測されています。静脈内療法（Intravenous the... もっと見る
サマリー世界の静脈内（IV）療法と静脈アクセス市場は、2020年に228億893万ドルとなり、2021年から2030年までのCAGRは5.2%を記録し、2030年には375億3,718万ドルに達すると予測されています。静脈内療法（Intravenous therapy: IV）は、液体、薬物、栄養素を患者の静脈に直接投与する医療技術です。静脈内投与は、水分補給や、精神状態の低下などにより口から食物や水を摂取できない、あるいは摂取しようとしない人への栄養補給によく用いられます。さらに、電解質の不均衡を是正するための血液製剤や電解質など、薬物やその他の医療用液体を投与するためにも使用される。心筋梗塞や脳梗塞、中毒などの病気の治療にも使われます。このような場合、患者は一刻も早く薬物治療を受けなければならないため、点滴薬が処方される。点滴療法と静脈アクセスデバイス市場の成長を促進する主な要因は、慢性疾患の発生率および有病率の上昇、交通事故の増加、外傷事例の急増が含まれています。また、医療費支出や医療保険の増加も、予測期間中の市場成長に拍車をかけると思われます。しかし、経験豊富な医療従事者の不足が市場の成長を制約しています。逆に、クリティカルケア治療の増加や老年人口の増加が、市場成長の主な要因となっています。 さらに、静脈内治療と静脈アクセス市場は、タイプ、医療用途、地域に基づいて区分されています。タイプ別では、植込み型ポート、IVカテーテル、皮下注射針、輸液ポンプ、その他の製品に分類されます。医療用途別では、体積膨張剤、投薬、血液ベース製品、栄養・緩衝液に分類されます。エンドユーザー別では、病院、外来手術センター、診療所などに細分化されます。地域別では、北米、欧州、アジア太平洋地域、LAMEAに分かれて分析されています。 世界の輸液療法・静脈アクセス市場で活動する主要企業には、Becton, Dickinson & Company、Braun Melsungen AG、テルモ医療法人、Teleflex Medical Inc.、Medtronic Inc.、Angiodynamic, Inc.、Smith& Nephew Plc、Pfizer Inc、Insulet Corporation、およびFresenius SE& CO.KGAAである。 バリューチェーンにおけるその他のプレイヤー（これらのプレイヤーのプロフィールはレポートではカバーしていません）には、Baxter International Inc.、iRadimed Corporation、BioScrip, Inc.、Grifols, S.A.、JW Life Science Co.Ltd.、BRIEF-Sichuan Kelun Pharmaceutical Co.Ltd.、CVS Health Corporation、Vifor Pharma Groupが含まれます。 目次CHAPTER 1:INTRODUCTION1.1.Report description 1.2.Key market segments 1.3.Key benefits to the stakeholders 1.4.Research Methodology 1.4.1.Secondary research 1.4.2.Primary research 1.4.3.Analyst tools and models CHAPTER 2:EXECUTIVE SUMMARY 2.1.Key findings of the study 2.2.CXO Perspective CHAPTER 3:MARKET OVERVIEW 3.1.Market definition and scope 3.2.Key findings 3.2.1.Top investment pockets 3.3.Porter’s five forces analysis 3.4.Top player positioning 3.5.Market dynamics 3.5.1.Drivers 3.5.2.Restraints 3.5.3.Opportunities 3.6.COVID-19 Impact Analysis on the market CHAPTER 4: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE 4.1 Overview 4.1.1 Market size and forecast 4.2 Implantable Ports 4.2.1 Key market trends, growth factors and opportunities 4.2.2 Market size and forecast, by region 4.2.3 Market analysis by country 4.3 Intravenous Catheters 4.3.1 Key market trends, growth factors and opportunities 4.3.2 Market size and forecast, by region 4.3.3 Market analysis by country 4.4 Hypodermic Needles 4.4.1 Key market trends, growth factors and opportunities 4.4.2 Market size and forecast, by region 4.4.3 Market analysis by country 4.5 Infusion Pumps 4.5.1 Key market trends, growth factors and opportunities 4.5.2 Market size and forecast, by region 4.5.3 Market analysis by country 4.6 Other 4.6.1 Key market trends, growth factors and opportunities 4.6.2 Market size and forecast, by region 4.6.3 Market analysis by country CHAPTER 5: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION 5.1 Overview 5.1.1 Market size and forecast 5.2 Volume Expander 5.2.1 Key market trends, growth factors and opportunities 5.2.2 Market size and forecast, by region 5.2.3 Market analysis by country 5.3 Medication Administration 5.3.1 Key market trends, growth factors and opportunities 5.3.2 Market size and forecast, by region 5.3.3 Market analysis by country 5.4 Blood Based Products 5.4.1 Key market trends, growth factors and opportunities 5.4.2 Market size and forecast, by region 5.4.3 Market analysis by country 5.5 Nutrition And Buffer Solution 5.5.1 Key market trends, growth factors and opportunities 5.5.2 Market size and forecast, by region 5.5.3 Market analysis by country CHAPTER 6: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER 6.1 Overview 6.1.1 Market size and forecast 6.2 Hospitals 6.2.1 Key market trends, growth factors and opportunities 6.2.2 Market size and forecast, by region 6.2.3 Market analysis by country 6.3 Ambulatory Surgical Center 6.3.1 Key market trends, growth factors and opportunities 6.3.2 Market size and forecast, by region 6.3.3 Market analysis by country 6.4 Clinics 6.4.1 Key market trends, growth factors and opportunities 6.4.2 Market size and forecast, by region 6.4.3 Market analysis by country CHAPTER 7: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY REGION 7.1 Overview 7.1.1 Market size and forecast 7.2 North America 7.2.1 Key trends and opportunities 7.2.2 North America Market size and forecast, by Type 7.2.3 North America Market size and forecast, by Medical Application 7.2.4 North America Market size and forecast, by End User 7.2.5 North America Market size and forecast, by country 7.2.5.1 U.S. 7.2.5.1.1 Market size and forecast, by Type 7.2.5.1.2 Market size and forecast, by Medical Application 7.2.5.1.3 Market size and forecast, by End User 7.2.5.2 Canada 7.2.5.2.1 Market size and forecast, by Type 7.2.5.2.2 Market size and forecast, by Medical Application 7.2.5.2.3 Market size and forecast, by End User 7.2.5.3 Mexico 7.2.5.3.1 Market size and forecast, by Type 7.2.5.3.2 Market size and forecast, by Medical Application 7.2.5.3.3 Market size and forecast, by End User 7.3 Europe 7.3.1 Key trends and opportunities 7.3.2 Europe Market size and forecast, by Type 7.3.3 Europe Market size and forecast, by Medical Application 7.3.4 Europe Market size and forecast, by End User 7.3.5 Europe Market size and forecast, by country 7.3.5.1 Germany 7.3.5.1.1 Market size and forecast, by Type 7.3.5.1.2 Market size and forecast, by Medical Application 7.3.5.1.3 Market size and forecast, by End User 7.3.5.2 France 7.3.5.2.1 Market size and forecast, by Type 7.3.5.2.2 Market size and forecast, by Medical Application 7.3.5.2.3 Market size and forecast, by End User 7.3.5.3 U.K. 7.3.5.3.1 Market size and forecast, by Type 7.3.5.3.2 Market size and forecast, by Medical Application 7.3.5.3.3 Market size and forecast, by End User 7.3.5.4 Italy 7.3.5.4.1 Market size and forecast, by Type 7.3.5.4.2 Market size and forecast, by Medical Application 7.3.5.4.3 Market size and forecast, by End User 7.3.5.5 Spain 7.3.5.5.1 Market size and forecast, by Type 7.3.5.5.2 Market size and forecast, by Medical Application 7.3.5.5.3 Market size and forecast, by End User 7.3.5.6 Rest of Europe 7.3.5.6.1 Market size and forecast, by Type 7.3.5.6.2 Market size and forecast, by Medical Application 7.3.5.6.3 Market size and forecast, by End User 7.4 Asia-Pacific 7.4.1 Key trends and opportunities 7.4.2 Asia-Pacific Market size and forecast, by Type 7.4.3 Asia-Pacific Market size and forecast, by Medical Application 7.4.4 Asia-Pacific Market size and forecast, by End User 7.4.5 Asia-Pacific Market size and forecast, by country 7.4.5.1 Japan 7.4.5.1.1 Market size and forecast, by Type 7.4.5.1.2 Market size and forecast, by Medical Application 7.4.5.1.3 Market size and forecast, by End User 7.4.5.2 China 7.4.5.2.1 Market size and forecast, by Type 7.4.5.2.2 Market size and forecast, by Medical Application 7.4.5.2.3 Market size and forecast, by End User 7.4.5.3 Australia 7.4.5.3.1 Market size and forecast, by Type 7.4.5.3.2 Market size and forecast, by Medical Application 7.4.5.3.3 Market size and forecast, by End User 7.4.5.4 India 7.4.5.4.1 Market size and forecast, by Type 7.4.5.4.2 Market size and forecast, by Medical Application 7.4.5.4.3 Market size and forecast, by End User 7.4.5.5 South Korea 7.4.5.5.1 Market size and forecast, by Type 7.4.5.5.2 Market size and forecast, by Medical Application 7.4.5.5.3 Market size and forecast, by End User 7.4.5.6 Rest Of Asia Pacific 7.4.5.6.1 Market size and forecast, by Type 7.4.5.6.2 Market size and forecast, by Medical Application 7.4.5.6.3 Market size and forecast, by End User 7.5 LAMEA 7.5.1 Key trends and opportunities 7.5.2 LAMEA Market size and forecast, by Type 7.5.3 LAMEA Market size and forecast, by Medical Application 7.5.4 LAMEA Market size and forecast, by End User 7.5.5 LAMEA Market size and forecast, by country 7.5.5.1 Brazil 7.5.5.1.1 Market size and forecast, by Type 7.5.5.1.2 Market size and forecast, by Medical Application 7.5.5.1.3 Market size and forecast, by End User 7.5.5.2 South Africa, 7.5.5.2.1 Market size and forecast, by Type 7.5.5.2.2 Market size and forecast, by Medical Application 7.5.5.2.3 Market size and forecast, by End User 7.5.5.3 Saudi Arabia 7.5.5.3.1 Market size and forecast, by Type 7.5.5.3.2 Market size and forecast, by Medical Application 7.5.5.3.3 Market size and forecast, by End User 7.5.5.4 Rest of LAMEA 7.5.5.4.1 Market size and forecast, by Type 7.5.5.4.2 Market size and forecast, by Medical Application 7.5.5.4.3 Market size and forecast, by End User CHAPTER 8: COMPANY LANDSCAPE 8.1. Introduction 8.2. Top winning strategies 8.3. Product Mapping of Top 10 Player 8.4. Competitive Dashboard 8.5. Competitive Heatmap 8.6. Key developments CHAPTER 9: COMPANY PROFILES 9.1 Medtronic Inc 9.1.1 Company overview 9.1.2 Company snapshot 9.1.3 Operating business segments 9.1.4 Product portfolio 9.1.5 Business performance 9.1.6 Key strategic moves and developments 9.2 Teleflex 9.2.1 Company overview 9.2.2 Company snapshot 9.2.3 Operating business segments 9.2.4 Product portfolio 9.2.5 Business performance 9.2.6 Key strategic moves and developments 9.3 B. Braun Melunsung 9.3.1 Company overview 9.3.2 Company snapshot 9.3.3 Operating business segments 9.3.4 Product portfolio 9.3.5 Business performance 9.3.6 Key strategic moves and developments 9.4 terumo corporation 9.4.1 Company overview 9.4.2 Company snapshot 9.4.3 Operating business segments 9.4.4 Product portfolio 9.4.5 Business performance 9.4.6 Key strategic moves and developments 9.5 AngioDynamics, Inc. 9.5.1 Company overview 9.5.2 Company snapshot 9.5.3 Operating business segments 9.5.4 Product portfolio 9.5.5 Business performance 9.5.6 Key strategic moves and developments 9.6 Fresenius SE and Co. KGaA. 9.6.1 Company overview 9.6.2 Company snapshot 9.6.3 Operating business segments 9.6.4 Product portfolio 9.6.5 Business performance 9.6.6 Key strategic moves and developments 9.7 Baxter international plc 9.7.1 Company overview 9.7.2 Company snapshot 9.7.3 Operating business segments 9.7.4 Product portfolio 9.7.5 Business performance 9.7.6 Key strategic moves and developments 9.8 Pfizer Inc 9.8.1 Company overview 9.8.2 Company snapshot 9.8.3 Operating business segments 9.8.4 Product portfolio 9.8.5 Business performance 9.8.6 Key strategic moves and developments 9.9 Cardinal Health Inc. 9.9.1 Company overview 9.9.2 Company snapshot 9.9.3 Operating business segments 9.9.4 Product portfolio 9.9.5 Business performance 9.9.6 Key strategic moves and developments 9.10 smiths medical 9.10.1 Company overview 9.10.2 Company snapshot 9.10.3 Operating business segments 9.10.4 Product portfolio 9.10.5 Business performance 9.10.6 Key strategic moves and developments LIST OF TABLES TABLE 1. GLOBAL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION) TABLE 2. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR IMPLANTABLE PORTS, BY REGION , 2020-2030,($MILLION) TABLE 3. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET IMPLANTABLE PORTS BY COUNTRY, 2020-2030,($MILLION) TABLE 4. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR INTRAVENOUS CATHETERS, BY REGION , 2020-2030,($MILLION) TABLE 5. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET INTRAVENOUS CATHETERS BY COUNTRY, 2020-2030,($MILLION) TABLE 6. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR HYPODERMIC NEEDLES, BY REGION , 2020-2030,($MILLION) TABLE 7. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET HYPODERMIC NEEDLES BY COUNTRY, 2020-2030,($MILLION) TABLE 8. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR INFUSION PUMPS, BY REGION , 2020-2030,($MILLION) TABLE 9. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET INFUSION PUMPS BY COUNTRY, 2020-2030,($MILLION) TABLE 10. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR OTHER, BY REGION , 2020-2030,($MILLION) TABLE 11. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET OTHER BY COUNTRY, 2020-2030,($MILLION) TABLE 12. GLOBAL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION) TABLE 13. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR VOLUME EXPANDER, BY REGION , 2020-2030,($MILLION) TABLE 14. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET VOLUME EXPANDER BY COUNTRY, 2020-2030,($MILLION) TABLE 15. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR MEDICATION ADMINISTRATION, BY REGION , 2020-2030,($MILLION) TABLE 16. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET MEDICATION ADMINISTRATION BY COUNTRY, 2020-2030,($MILLION) TABLE 17. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR BLOOD BASED PRODUCTS, BY REGION , 2020-2030,($MILLION) TABLE 18. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BLOOD BASED PRODUCTS BY COUNTRY, 2020-2030,($MILLION) TABLE 19. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR NUTRITION AND BUFFER SOLUTION, BY REGION , 2020-2030,($MILLION) TABLE 20. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET NUTRITION AND BUFFER SOLUTION BY COUNTRY, 2020-2030,($MILLION) TABLE 21. GLOBAL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION) TABLE 22. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR HOSPITALS, BY REGION , 2020-2030,($MILLION) TABLE 23. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET HOSPITALS BY COUNTRY, 2020-2030,($MILLION) TABLE 24. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR AMBULATORY SURGICAL CENTER, BY REGION , 2020-2030,($MILLION) TABLE 25. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET AMBULATORY SURGICAL CENTER BY COUNTRY, 2020-2030,($MILLION) TABLE 26. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR CLINICS, BY REGION , 2020-2030,($MILLION) TABLE 27. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET CLINICS BY COUNTRY, 2020-2030,($MILLION) TABLE 28. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY REGION, 2020-2030,($MILLION) TABLE 29. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION) TABLE 30. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION) TABLE 31. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION) TABLE 32. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION) TABLE 33. U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 34. U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 35. U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 36. CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 37. CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 38. CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 39. MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 40. MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 41. MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 42. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION) TABLE 43. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION) TABLE 44. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION) TABLE 45. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION) TABLE 46. GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 47. GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 48. GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 49. FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 50. FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 51. FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 52. U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 53. U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 54. U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 55. ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 56. ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 57. ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 58. SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 59. SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 60. SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 61. REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 62. REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 63. REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 64. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION) TABLE 65. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION) TABLE 66. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION) TABLE 67. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION) TABLE 68. JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 69. JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 70. JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 71. CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 72. CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 73. CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 74. AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 75. AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 76. AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 77. INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 78. INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 79. INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 80. SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 81. SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 82. SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 83. REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 84. REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 85. REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 86. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION) TABLE 87. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION) TABLE 88. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION) TABLE 89. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION) TABLE 90. BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 91. BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 92. BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 93. SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 94. SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 95. SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 96. SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 97. SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 98. SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 99. REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 100. REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 101. REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 102.MEDTRONIC INC: COMPANY SNAPSHOT TABLE 103.MEDTRONIC INC: OPERATING SEGMENTS TABLE 104.MEDTRONIC INC: PRODUCT PORTFOLIO TABLE 105.MEDTRONIC INC: NET SALES, TABLE 106.MEDTRONIC INC: KEY STRATERGIES TABLE 107.TELEFLEX: COMPANY SNAPSHOT TABLE 108.TELEFLEX: OPERATING SEGMENTS TABLE 109.TELEFLEX: PRODUCT PORTFOLIO TABLE 110.TELEFLEX: NET SALES, TABLE 111.TELEFLEX: KEY STRATERGIES TABLE 112.B. BRAUN MELUNSUNG: COMPANY SNAPSHOT TABLE 113.B. BRAUN MELUNSUNG: OPERATING SEGMENTS TABLE 114.B. BRAUN MELUNSUNG: PRODUCT PORTFOLIO TABLE 115.B. BRAUN MELUNSUNG: NET SALES, TABLE 116.B. BRAUN MELUNSUNG: KEY STRATERGIES TABLE 117.TERUMO CORPORATION: COMPANY SNAPSHOT TABLE 118.TERUMO CORPORATION: OPERATING SEGMENTS TABLE 119.TERUMO CORPORATION: PRODUCT PORTFOLIO TABLE 120.TERUMO CORPORATION: NET SALES, TABLE 121.TERUMO CORPORATION: KEY STRATERGIES TABLE 122.ANGIODYNAMICS, INC.: COMPANY SNAPSHOT TABLE 123.ANGIODYNAMICS, INC.: OPERATING SEGMENTS TABLE 124.ANGIODYNAMICS, INC.: PRODUCT PORTFOLIO TABLE 125.ANGIODYNAMICS, INC.: NET SALES, TABLE 126.ANGIODYNAMICS, INC.: KEY STRATERGIES TABLE 127.FRESENIUS SE AND CO. KGAA.: COMPANY SNAPSHOT TABLE 128.FRESENIUS SE AND CO. KGAA.: OPERATING SEGMENTS TABLE 129.FRESENIUS SE AND CO. KGAA.: PRODUCT PORTFOLIO TABLE 130.FRESENIUS SE AND CO. KGAA.: NET SALES, TABLE 131.FRESENIUS SE AND CO. KGAA.: KEY STRATERGIES TABLE 132.BAXTER INTERNATIONAL PLC: COMPANY SNAPSHOT TABLE 133.BAXTER INTERNATIONAL PLC: OPERATING SEGMENTS TABLE 134.BAXTER INTERNATIONAL PLC: PRODUCT PORTFOLIO TABLE 135.BAXTER INTERNATIONAL PLC: NET SALES, TABLE 136.BAXTER INTERNATIONAL PLC: KEY STRATERGIES TABLE 137.PFIZER INC: COMPANY SNAPSHOT TABLE 138.PFIZER INC: OPERATING SEGMENTS TABLE 139.PFIZER INC: PRODUCT PORTFOLIO TABLE 140.PFIZER INC: NET SALES, TABLE 141.PFIZER INC: KEY STRATERGIES TABLE 142.CARDINAL HEALTH INC.: COMPANY SNAPSHOT TABLE 143.CARDINAL HEALTH INC.: OPERATING SEGMENTS TABLE 144.CARDINAL HEALTH INC.: PRODUCT PORTFOLIO TABLE 145.CARDINAL HEALTH INC.: NET SALES, TABLE 146.CARDINAL HEALTH INC.: KEY STRATERGIES TABLE 147.SMITHS MEDICAL: COMPANY SNAPSHOT TABLE 148.SMITHS MEDICAL: OPERATING SEGMENTS TABLE 149.SMITHS MEDICAL: PRODUCT PORTFOLIO TABLE 150.SMITHS MEDICAL: NET SALES, TABLE 151.SMITHS MEDICAL: KEY STRATERGIES LIST OF FIGURES FIGURE 1.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET SEGMENTATION FIGURE 2.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030 FIGURE 3.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030 FIGURE 4. TOP INVESTMENT POCKETS, BY REGION FIGURE 5.PORTER FIVE-1 FIGURE 6.PORTER FIVE-2 FIGURE 7.PORTER FIVE-3 FIGURE 8.PORTER FIVE-4 FIGURE 9.PORTER FIVE-5 FIGURE 10.TOP PLAYER POSITIONING FIGURE 11.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES FIGURE 11.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,BY TYPE,2020(%) FIGURE 12.COMPARATIVE SHARE ANALYSIS OF IMPLANTABLE PORTS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INTRAVENOUS CATHETERS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 14.COMPARATIVE SHARE ANALYSIS OF HYPODERMIC NEEDLES INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INFUSION PUMPS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHER INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 17.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,BY MEDICAL APPLICATION,2020(%) FIGURE 18.COMPARATIVE SHARE ANALYSIS OF VOLUME EXPANDER INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MEDICATION ADMINISTRATION INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 20.COMPARATIVE SHARE ANALYSIS OF BLOOD BASED PRODUCTS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 21.COMPARATIVE SHARE ANALYSIS OF NUTRITION AND BUFFER SOLUTION INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 22.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,BY END USER,2020(%) FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITALS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 24.COMPARATIVE SHARE ANALYSIS OF AMBULATORY SURGICAL CENTER INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CLINICS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 26.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY REGION,2020 FIGURE 27.U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 28.CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 29.MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 30.GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 31.FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 32.U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 33.ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 34.SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 35.REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 36.JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 37.CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 38.AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 39.INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 40.SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 41.REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 42.BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 43.SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 44.SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 45.REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 46. TOP WINNING STRATEGIES, BY YEAR FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS FIGURE 50.COMPETITIVE DASHBOARD FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS FIGURE 52.MEDTRONIC INC.: NET SALES ,($MILLION) FIGURE 53.TELEFLEX.: NET SALES ,($MILLION) FIGURE 54.B. BRAUN MELUNSUNG.: NET SALES ,($MILLION) FIGURE 55.TERUMO CORPORATION.: NET SALES ,($MILLION) FIGURE 56.ANGIODYNAMICS, INC..: NET SALES ,($MILLION) FIGURE 57.FRESENIUS SE AND CO. KGAA..: NET SALES ,($MILLION) FIGURE 58.BAXTER INTERNATIONAL PLC.: NET SALES ,($MILLION) FIGURE 59.PFIZER INC.: NET SALES ,($MILLION) FIGURE 60.CARDINAL HEALTH INC..: NET SALES ,($MILLION) FIGURE 61.SMITHS MEDICAL.: NET SALES ,($MILLION)
SummaryThe global intravenous (IV) therapy and vein access market was valued at $22,808.93 million in 2020 and is projected to reach $ 37,537.18 million by 2030, registering a CAGR of 5.2% from 2021 to 2030. Intravenous therapy (IV) is a medical technique that transfers fluids, medications, and nutrients directly into the veins of the patient. The intravenous route of administration is commonly used for rehydration or to provide nutrients for those who cannot, or will not—due to reduced mental states or otherwise—consume food or water by mouth. In addition, it is used to administer medications or other medical fluids, including blood products or electrolytes to correct electrolyte imbalances.. It is used for the treatment of diseases, including heart attack, stroke, and poisoning. In such cases, the patient must receive medication at the earliest, and hence IV medication is prescribed. Table of ContentsCHAPTER 1:INTRODUCTION1.1.Report description 1.2.Key market segments 1.3.Key benefits to the stakeholders 1.4.Research Methodology 1.4.1.Secondary research 1.4.2.Primary research 1.4.3.Analyst tools and models CHAPTER 2:EXECUTIVE SUMMARY 2.1.Key findings of the study 2.2.CXO Perspective CHAPTER 3:MARKET OVERVIEW 3.1.Market definition and scope 3.2.Key findings 3.2.1.Top investment pockets 3.3.Porter’s five forces analysis 3.4.Top player positioning 3.5.Market dynamics 3.5.1.Drivers 3.5.2.Restraints 3.5.3.Opportunities 3.6.COVID-19 Impact Analysis on the market CHAPTER 4: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE 4.1 Overview 4.1.1 Market size and forecast 4.2 Implantable Ports 4.2.1 Key market trends, growth factors and opportunities 4.2.2 Market size and forecast, by region 4.2.3 Market analysis by country 4.3 Intravenous Catheters 4.3.1 Key market trends, growth factors and opportunities 4.3.2 Market size and forecast, by region 4.3.3 Market analysis by country 4.4 Hypodermic Needles 4.4.1 Key market trends, growth factors and opportunities 4.4.2 Market size and forecast, by region 4.4.3 Market analysis by country 4.5 Infusion Pumps 4.5.1 Key market trends, growth factors and opportunities 4.5.2 Market size and forecast, by region 4.5.3 Market analysis by country 4.6 Other 4.6.1 Key market trends, growth factors and opportunities 4.6.2 Market size and forecast, by region 4.6.3 Market analysis by country CHAPTER 5: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION 5.1 Overview 5.1.1 Market size and forecast 5.2 Volume Expander 5.2.1 Key market trends, growth factors and opportunities 5.2.2 Market size and forecast, by region 5.2.3 Market analysis by country 5.3 Medication Administration 5.3.1 Key market trends, growth factors and opportunities 5.3.2 Market size and forecast, by region 5.3.3 Market analysis by country 5.4 Blood Based Products 5.4.1 Key market trends, growth factors and opportunities 5.4.2 Market size and forecast, by region 5.4.3 Market analysis by country 5.5 Nutrition And Buffer Solution 5.5.1 Key market trends, growth factors and opportunities 5.5.2 Market size and forecast, by region 5.5.3 Market analysis by country CHAPTER 6: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER 6.1 Overview 6.1.1 Market size and forecast 6.2 Hospitals 6.2.1 Key market trends, growth factors and opportunities 6.2.2 Market size and forecast, by region 6.2.3 Market analysis by country 6.3 Ambulatory Surgical Center 6.3.1 Key market trends, growth factors and opportunities 6.3.2 Market size and forecast, by region 6.3.3 Market analysis by country 6.4 Clinics 6.4.1 Key market trends, growth factors and opportunities 6.4.2 Market size and forecast, by region 6.4.3 Market analysis by country CHAPTER 7: INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY REGION 7.1 Overview 7.1.1 Market size and forecast 7.2 North America 7.2.1 Key trends and opportunities 7.2.2 North America Market size and forecast, by Type 7.2.3 North America Market size and forecast, by Medical Application 7.2.4 North America Market size and forecast, by End User 7.2.5 North America Market size and forecast, by country 7.2.5.1 U.S. 7.2.5.1.1 Market size and forecast, by Type 7.2.5.1.2 Market size and forecast, by Medical Application 7.2.5.1.3 Market size and forecast, by End User 7.2.5.2 Canada 7.2.5.2.1 Market size and forecast, by Type 7.2.5.2.2 Market size and forecast, by Medical Application 7.2.5.2.3 Market size and forecast, by End User 7.2.5.3 Mexico 7.2.5.3.1 Market size and forecast, by Type 7.2.5.3.2 Market size and forecast, by Medical Application 7.2.5.3.3 Market size and forecast, by End User 7.3 Europe 7.3.1 Key trends and opportunities 7.3.2 Europe Market size and forecast, by Type 7.3.3 Europe Market size and forecast, by Medical Application 7.3.4 Europe Market size and forecast, by End User 7.3.5 Europe Market size and forecast, by country 7.3.5.1 Germany 7.3.5.1.1 Market size and forecast, by Type 7.3.5.1.2 Market size and forecast, by Medical Application 7.3.5.1.3 Market size and forecast, by End User 7.3.5.2 France 7.3.5.2.1 Market size and forecast, by Type 7.3.5.2.2 Market size and forecast, by Medical Application 7.3.5.2.3 Market size and forecast, by End User 7.3.5.3 U.K. 7.3.5.3.1 Market size and forecast, by Type 7.3.5.3.2 Market size and forecast, by Medical Application 7.3.5.3.3 Market size and forecast, by End User 7.3.5.4 Italy 7.3.5.4.1 Market size and forecast, by Type 7.3.5.4.2 Market size and forecast, by Medical Application 7.3.5.4.3 Market size and forecast, by End User 7.3.5.5 Spain 7.3.5.5.1 Market size and forecast, by Type 7.3.5.5.2 Market size and forecast, by Medical Application 7.3.5.5.3 Market size and forecast, by End User 7.3.5.6 Rest of Europe 7.3.5.6.1 Market size and forecast, by Type 7.3.5.6.2 Market size and forecast, by Medical Application 7.3.5.6.3 Market size and forecast, by End User 7.4 Asia-Pacific 7.4.1 Key trends and opportunities 7.4.2 Asia-Pacific Market size and forecast, by Type 7.4.3 Asia-Pacific Market size and forecast, by Medical Application 7.4.4 Asia-Pacific Market size and forecast, by End User 7.4.5 Asia-Pacific Market size and forecast, by country 7.4.5.1 Japan 7.4.5.1.1 Market size and forecast, by Type 7.4.5.1.2 Market size and forecast, by Medical Application 7.4.5.1.3 Market size and forecast, by End User 7.4.5.2 China 7.4.5.2.1 Market size and forecast, by Type 7.4.5.2.2 Market size and forecast, by Medical Application 7.4.5.2.3 Market size and forecast, by End User 7.4.5.3 Australia 7.4.5.3.1 Market size and forecast, by Type 7.4.5.3.2 Market size and forecast, by Medical Application 7.4.5.3.3 Market size and forecast, by End User 7.4.5.4 India 7.4.5.4.1 Market size and forecast, by Type 7.4.5.4.2 Market size and forecast, by Medical Application 7.4.5.4.3 Market size and forecast, by End User 7.4.5.5 South Korea 7.4.5.5.1 Market size and forecast, by Type 7.4.5.5.2 Market size and forecast, by Medical Application 7.4.5.5.3 Market size and forecast, by End User 7.4.5.6 Rest Of Asia Pacific 7.4.5.6.1 Market size and forecast, by Type 7.4.5.6.2 Market size and forecast, by Medical Application 7.4.5.6.3 Market size and forecast, by End User 7.5 LAMEA 7.5.1 Key trends and opportunities 7.5.2 LAMEA Market size and forecast, by Type 7.5.3 LAMEA Market size and forecast, by Medical Application 7.5.4 LAMEA Market size and forecast, by End User 7.5.5 LAMEA Market size and forecast, by country 7.5.5.1 Brazil 7.5.5.1.1 Market size and forecast, by Type 7.5.5.1.2 Market size and forecast, by Medical Application 7.5.5.1.3 Market size and forecast, by End User 7.5.5.2 South Africa, 7.5.5.2.1 Market size and forecast, by Type 7.5.5.2.2 Market size and forecast, by Medical Application 7.5.5.2.3 Market size and forecast, by End User 7.5.5.3 Saudi Arabia 7.5.5.3.1 Market size and forecast, by Type 7.5.5.3.2 Market size and forecast, by Medical Application 7.5.5.3.3 Market size and forecast, by End User 7.5.5.4 Rest of LAMEA 7.5.5.4.1 Market size and forecast, by Type 7.5.5.4.2 Market size and forecast, by Medical Application 7.5.5.4.3 Market size and forecast, by End User CHAPTER 8: COMPANY LANDSCAPE 8.1. Introduction 8.2. Top winning strategies 8.3. Product Mapping of Top 10 Player 8.4. Competitive Dashboard 8.5. Competitive Heatmap 8.6. Key developments CHAPTER 9: COMPANY PROFILES 9.1 Medtronic Inc 9.1.1 Company overview 9.1.2 Company snapshot 9.1.3 Operating business segments 9.1.4 Product portfolio 9.1.5 Business performance 9.1.6 Key strategic moves and developments 9.2 Teleflex 9.2.1 Company overview 9.2.2 Company snapshot 9.2.3 Operating business segments 9.2.4 Product portfolio 9.2.5 Business performance 9.2.6 Key strategic moves and developments 9.3 B. Braun Melunsung 9.3.1 Company overview 9.3.2 Company snapshot 9.3.3 Operating business segments 9.3.4 Product portfolio 9.3.5 Business performance 9.3.6 Key strategic moves and developments 9.4 terumo corporation 9.4.1 Company overview 9.4.2 Company snapshot 9.4.3 Operating business segments 9.4.4 Product portfolio 9.4.5 Business performance 9.4.6 Key strategic moves and developments 9.5 AngioDynamics, Inc. 9.5.1 Company overview 9.5.2 Company snapshot 9.5.3 Operating business segments 9.5.4 Product portfolio 9.5.5 Business performance 9.5.6 Key strategic moves and developments 9.6 Fresenius SE and Co. KGaA. 9.6.1 Company overview 9.6.2 Company snapshot 9.6.3 Operating business segments 9.6.4 Product portfolio 9.6.5 Business performance 9.6.6 Key strategic moves and developments 9.7 Baxter international plc 9.7.1 Company overview 9.7.2 Company snapshot 9.7.3 Operating business segments 9.7.4 Product portfolio 9.7.5 Business performance 9.7.6 Key strategic moves and developments 9.8 Pfizer Inc 9.8.1 Company overview 9.8.2 Company snapshot 9.8.3 Operating business segments 9.8.4 Product portfolio 9.8.5 Business performance 9.8.6 Key strategic moves and developments 9.9 Cardinal Health Inc. 9.9.1 Company overview 9.9.2 Company snapshot 9.9.3 Operating business segments 9.9.4 Product portfolio 9.9.5 Business performance 9.9.6 Key strategic moves and developments 9.10 smiths medical 9.10.1 Company overview 9.10.2 Company snapshot 9.10.3 Operating business segments 9.10.4 Product portfolio 9.10.5 Business performance 9.10.6 Key strategic moves and developments LIST OF TABLES TABLE 1. GLOBAL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION) TABLE 2. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR IMPLANTABLE PORTS, BY REGION , 2020-2030,($MILLION) TABLE 3. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET IMPLANTABLE PORTS BY COUNTRY, 2020-2030,($MILLION) TABLE 4. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR INTRAVENOUS CATHETERS, BY REGION , 2020-2030,($MILLION) TABLE 5. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET INTRAVENOUS CATHETERS BY COUNTRY, 2020-2030,($MILLION) TABLE 6. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR HYPODERMIC NEEDLES, BY REGION , 2020-2030,($MILLION) TABLE 7. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET HYPODERMIC NEEDLES BY COUNTRY, 2020-2030,($MILLION) TABLE 8. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR INFUSION PUMPS, BY REGION , 2020-2030,($MILLION) TABLE 9. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET INFUSION PUMPS BY COUNTRY, 2020-2030,($MILLION) TABLE 10. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR OTHER, BY REGION , 2020-2030,($MILLION) TABLE 11. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET OTHER BY COUNTRY, 2020-2030,($MILLION) TABLE 12. GLOBAL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION) TABLE 13. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR VOLUME EXPANDER, BY REGION , 2020-2030,($MILLION) TABLE 14. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET VOLUME EXPANDER BY COUNTRY, 2020-2030,($MILLION) TABLE 15. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR MEDICATION ADMINISTRATION, BY REGION , 2020-2030,($MILLION) TABLE 16. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET MEDICATION ADMINISTRATION BY COUNTRY, 2020-2030,($MILLION) TABLE 17. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR BLOOD BASED PRODUCTS, BY REGION , 2020-2030,($MILLION) TABLE 18. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BLOOD BASED PRODUCTS BY COUNTRY, 2020-2030,($MILLION) TABLE 19. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR NUTRITION AND BUFFER SOLUTION, BY REGION , 2020-2030,($MILLION) TABLE 20. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET NUTRITION AND BUFFER SOLUTION BY COUNTRY, 2020-2030,($MILLION) TABLE 21. GLOBAL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION) TABLE 22. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR HOSPITALS, BY REGION , 2020-2030,($MILLION) TABLE 23. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET HOSPITALS BY COUNTRY, 2020-2030,($MILLION) TABLE 24. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR AMBULATORY SURGICAL CENTER, BY REGION , 2020-2030,($MILLION) TABLE 25. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET AMBULATORY SURGICAL CENTER BY COUNTRY, 2020-2030,($MILLION) TABLE 26. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET REVENUE, FOR CLINICS, BY REGION , 2020-2030,($MILLION) TABLE 27. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET CLINICS BY COUNTRY, 2020-2030,($MILLION) TABLE 28. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY REGION, 2020-2030,($MILLION) TABLE 29. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION) TABLE 30. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION) TABLE 31. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION) TABLE 32. NORTH AMERICA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION) TABLE 33. U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 34. U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 35. U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 36. CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 37. CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 38. CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 39. MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 40. MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 41. MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 42. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION) TABLE 43. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION) TABLE 44. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION) TABLE 45. EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION) TABLE 46. GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 47. GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 48. GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 49. FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 50. FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 51. FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 52. U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 53. U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 54. U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 55. ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 56. ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 57. ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 58. SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 59. SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 60. SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 61. REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 62. REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 63. REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 64. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION) TABLE 65. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION) TABLE 66. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION) TABLE 67. ASIA-PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION) TABLE 68. JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 69. JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 70. JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 71. CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 72. CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 73. CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 74. AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 75. AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 76. AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 77. INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 78. INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 79. INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 80. SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 81. SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 82. SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 83. REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 84. REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 85. REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 86. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY TYPE, 2020-2030,($MILLION) TABLE 87. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY MEDICAL APPLICATION, 2020-2030,($MILLION) TABLE 88. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY END USER, 2020-2030,($MILLION) TABLE 89. LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET, BY COUNTRY, 2020-2030,($MILLION) TABLE 90. BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 91. BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 92. BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 93. SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 94. SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 95. SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 96. SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 97. SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 98. SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 99. REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY TYPE 2020-2030,($MILLION) TABLE 100. REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY MEDICAL APPLICATION 2020-2030,($MILLION) TABLE 101. REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY END USER 2020-2030,($MILLION) TABLE 102.MEDTRONIC INC: COMPANY SNAPSHOT TABLE 103.MEDTRONIC INC: OPERATING SEGMENTS TABLE 104.MEDTRONIC INC: PRODUCT PORTFOLIO TABLE 105.MEDTRONIC INC: NET SALES, TABLE 106.MEDTRONIC INC: KEY STRATERGIES TABLE 107.TELEFLEX: COMPANY SNAPSHOT TABLE 108.TELEFLEX: OPERATING SEGMENTS TABLE 109.TELEFLEX: PRODUCT PORTFOLIO TABLE 110.TELEFLEX: NET SALES, TABLE 111.TELEFLEX: KEY STRATERGIES TABLE 112.B. BRAUN MELUNSUNG: COMPANY SNAPSHOT TABLE 113.B. BRAUN MELUNSUNG: OPERATING SEGMENTS TABLE 114.B. BRAUN MELUNSUNG: PRODUCT PORTFOLIO TABLE 115.B. BRAUN MELUNSUNG: NET SALES, TABLE 116.B. BRAUN MELUNSUNG: KEY STRATERGIES TABLE 117.TERUMO CORPORATION: COMPANY SNAPSHOT TABLE 118.TERUMO CORPORATION: OPERATING SEGMENTS TABLE 119.TERUMO CORPORATION: PRODUCT PORTFOLIO TABLE 120.TERUMO CORPORATION: NET SALES, TABLE 121.TERUMO CORPORATION: KEY STRATERGIES TABLE 122.ANGIODYNAMICS, INC.: COMPANY SNAPSHOT TABLE 123.ANGIODYNAMICS, INC.: OPERATING SEGMENTS TABLE 124.ANGIODYNAMICS, INC.: PRODUCT PORTFOLIO TABLE 125.ANGIODYNAMICS, INC.: NET SALES, TABLE 126.ANGIODYNAMICS, INC.: KEY STRATERGIES TABLE 127.FRESENIUS SE AND CO. KGAA.: COMPANY SNAPSHOT TABLE 128.FRESENIUS SE AND CO. KGAA.: OPERATING SEGMENTS TABLE 129.FRESENIUS SE AND CO. KGAA.: PRODUCT PORTFOLIO TABLE 130.FRESENIUS SE AND CO. KGAA.: NET SALES, TABLE 131.FRESENIUS SE AND CO. KGAA.: KEY STRATERGIES TABLE 132.BAXTER INTERNATIONAL PLC: COMPANY SNAPSHOT TABLE 133.BAXTER INTERNATIONAL PLC: OPERATING SEGMENTS TABLE 134.BAXTER INTERNATIONAL PLC: PRODUCT PORTFOLIO TABLE 135.BAXTER INTERNATIONAL PLC: NET SALES, TABLE 136.BAXTER INTERNATIONAL PLC: KEY STRATERGIES TABLE 137.PFIZER INC: COMPANY SNAPSHOT TABLE 138.PFIZER INC: OPERATING SEGMENTS TABLE 139.PFIZER INC: PRODUCT PORTFOLIO TABLE 140.PFIZER INC: NET SALES, TABLE 141.PFIZER INC: KEY STRATERGIES TABLE 142.CARDINAL HEALTH INC.: COMPANY SNAPSHOT TABLE 143.CARDINAL HEALTH INC.: OPERATING SEGMENTS TABLE 144.CARDINAL HEALTH INC.: PRODUCT PORTFOLIO TABLE 145.CARDINAL HEALTH INC.: NET SALES, TABLE 146.CARDINAL HEALTH INC.: KEY STRATERGIES TABLE 147.SMITHS MEDICAL: COMPANY SNAPSHOT TABLE 148.SMITHS MEDICAL: OPERATING SEGMENTS TABLE 149.SMITHS MEDICAL: PRODUCT PORTFOLIO TABLE 150.SMITHS MEDICAL: NET SALES, TABLE 151.SMITHS MEDICAL: KEY STRATERGIES LIST OF FIGURES FIGURE 1.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET SEGMENTATION FIGURE 2.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030 FIGURE 3.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030 FIGURE 4. TOP INVESTMENT POCKETS, BY REGION FIGURE 5.PORTER FIVE-1 FIGURE 6.PORTER FIVE-2 FIGURE 7.PORTER FIVE-3 FIGURE 8.PORTER FIVE-4 FIGURE 9.PORTER FIVE-5 FIGURE 10.TOP PLAYER POSITIONING FIGURE 11.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES FIGURE 11.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,BY TYPE,2020(%) FIGURE 12.COMPARATIVE SHARE ANALYSIS OF IMPLANTABLE PORTS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INTRAVENOUS CATHETERS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 14.COMPARATIVE SHARE ANALYSIS OF HYPODERMIC NEEDLES INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INFUSION PUMPS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHER INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 17.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,BY MEDICAL APPLICATION,2020(%) FIGURE 18.COMPARATIVE SHARE ANALYSIS OF VOLUME EXPANDER INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MEDICATION ADMINISTRATION INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 20.COMPARATIVE SHARE ANALYSIS OF BLOOD BASED PRODUCTS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 21.COMPARATIVE SHARE ANALYSIS OF NUTRITION AND BUFFER SOLUTION INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 22.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,BY END USER,2020(%) FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITALS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 24.COMPARATIVE SHARE ANALYSIS OF AMBULATORY SURGICAL CENTER INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CLINICS INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030(%) FIGURE 26.INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET BY REGION,2020 FIGURE 27.U.S. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 28.CANADA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 29.MEXICO INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 30.GERMANY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 31.FRANCE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 32.U.K. INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 33.ITALY INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 34.SPAIN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 35.REST OF EUROPE INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 36.JAPAN INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 37.CHINA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 38.AUSTRALIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 39.INDIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 40.SOUTH KOREA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 41.REST OF ASIA PACIFIC INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 42.BRAZIL INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 43.SOUTH AFRICA, INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 44.SAUDI ARABIA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 45.REST OF LAMEA INTRAVENOUS (IV) THERAPY AND VEIN ACCESS MARKET,2020-2030($MILLION) FIGURE 46. TOP WINNING STRATEGIES, BY YEAR FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS FIGURE 50.COMPETITIVE DASHBOARD FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS FIGURE 52.MEDTRONIC INC.: NET SALES ,($MILLION) FIGURE 53.TELEFLEX.: NET SALES ,($MILLION) FIGURE 54.B. BRAUN MELUNSUNG.: NET SALES ,($MILLION) FIGURE 55.TERUMO CORPORATION.: NET SALES ,($MILLION) FIGURE 56.ANGIODYNAMICS, INC..: NET SALES ,($MILLION) FIGURE 57.FRESENIUS SE AND CO. KGAA..: NET SALES ,($MILLION) FIGURE 58.BAXTER INTERNATIONAL PLC.: NET SALES ,($MILLION) FIGURE 59.PFIZER INC.: NET SALES ,($MILLION) FIGURE 60.CARDINAL HEALTH INC..: NET SALES ,($MILLION) FIGURE 61.SMITHS MEDICAL.: NET SALES ,($MILLION)
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Allied Market Research社のその他分野での最新刊レポート
本レポートと同じKEY WORD（catheters）の最新刊レポート
よくあるご質問Allied Market Research社はどのような調査会社ですか?アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
